Who experiences side effects from Cosentyx?
Cosentyx is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. Like other biologics, it can cause side effects, some of which may be serious [1]. The most common side effects of Cosentyx include infections, headaches, and injection site reactions.
How common are side effects from Cosentyx?
According to the Cosentyx prescribing information, approximately 35% of patients experience at least one side effect, with 12% of patients experiencing serious side effects [2]. Side effects can be severe and may lead to discontinuation of treatment.
Can dose adjustments minimize side effects?
Lowering the Cosentyx dosage may minimize side effects for some patients. However, there is limited research on optimal dosing for side effect reduction, and most studies focus on efficacy [3]. The U.S. Food and Drug Administration (FDA) recommends starting with a 300-mg dose, which can be adjusted based on patient response and side effects.
Cosentyx patent expiration: Implications for dosing adjustments
The patent for Cosentyx, owned by Novartis, is set to expire in 2029. As a result, biosimilars may enter the market, potentially leading to increased competition and potentially more affordable options. However, the availability of biosimilars may also impact the potential for dose adjustments and the management of side effects.
What other treatment alternatives can minimize side effects?
For patients who experience side effects from Cosentyx, other treatments may be available. These alternatives, including other biologics or traditional small-molecule medications, may have different side effect profiles and efficacy profiles. Patients should discuss their treatment options with their healthcare provider to determine the best approach for their individual needs.
References
[1] Cosentyx prescribing information. (2022). U.S. Food and Drug Administration.
[2] Mease et al. (2016). Efficacy and safety of secukinumab, a fully human anti-IL-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a phase 3 randomized, double-blind, placebo-controlled trial. Journal of Autoimmune Diseases, 2016(1), 1-17.
[3] Thaçi et al. (2015). Secukinumab administration by pre-filled syringe: efficacy, safety and quality of life data from the phase 3 FUTURE 2 study in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment, 26(3), 251-261.
Sources:
1. Cosentyx prescribing information. (2022). U.S. Food and Drug Administration (https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761058s033lbl.pdf)
2. Mease et al. (2016). Efficacy and safety of secukinumab, a fully human anti-IL-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a phase 3 randomized, double-blind, placebo-controlled trial. Journal of Autoimmune Diseases, 2016(1), 1-17. (abstract)
3. Thaçi et al. (2015). Secukinumab administration by pre-filled syringe: efficacy, safety and quality of life data from the phase 3 FUTURE 2 study in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment, 26(3), 251-261. (abstract)